Literature DB >> 30666744

T mapping for assessment of renal allograft fibrosis.

Stefanie J Hectors1,2, Octavia Bane1,2, Paul Kennedy1,2, Fadi El Salem3, Madhav Menon4, Maxwell Segall1,2, Rafael Khaim4, Veronica Delaney4, Sara Lewis1,2, Bachir Taouli1,2.   

Abstract

BACKGROUND: There is an unmet need for noninvasive methods to diagnose and stage renal allograft fibrosis.
PURPOSE: To investigate the utility of T1ρ measured with MRI for the assessment of fibrosis in renal allografts. STUDY TYPE: Institutional Review Board (IRB)-approved prospective.
SUBJECTS: Fifteen patients with stable functional allograft (M/F 9/6, mean age 56 years) and 12 patients with allograft dysfunction and established fibrosis (M/F 6/6, mean age 51 years). FIELD STRENGTH/SEQUENCE: T1ρ imaging at 1.5T using a custom-developed sequence. ASSESSMENT: Average T1ρ in the cortex and medulla was quantified and T1ρ repeatability (expressed by the coefficient of variation [CV]) was measured in four patients. STATISTICAL TESTS: Differences in T1ρ values between the 2 groups were assessed using Mann-Whitney U-tests. Diagnostic performance of T1ρ for differentiation between functional and fibrotic allografts was evaluated using receiver operating characteristic (ROC) analysis. Spearman correlations of T1ρ with Masson's trichrome-stained fractions and serum estimated glomerular filtration rate (eGFR) were assessed.
RESULTS: Higher T1ρ repeatability was found for cortex compared with medulla (mean CV T1ρ cortex 7.4%, medulla 13.3%). T1ρ values were significantly higher in the cortex of fibrotic vs. functional allografts (111.8 ± 17.2 msec vs. 99.0 ± 11.0 msec, P = 0.027), while there was no difference in medullary T1ρ values (122.6 ± 20.8 msec vs. 124.3 ± 20.8 msec, P = 0.789). Cortical T1ρ significantly correlated with Masson's trichrome-stained fractions (r = 0.515, P = 0.044) and eGFR (r = -0.546, P = 0.004), and demonstrated an area under the curve (AUC) of 0.77 for differentiating between functional and fibrotic allografts (sensitivity and specificity of 75.0% and 86.7%, using threshold of 106.9 msec). DATA
CONCLUSION: Our preliminary results suggest that T1ρ is a potential imaging biomarker of renal allograft fibrosis. These results should be verified in a larger study. LEVEL OF EVIDENCE: 1 Technical Efficacy: Stage 1 J. Magn. Reson. Imaging 2019;50:1085-1091.
© 2019 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  T1rho; fibrosis; renal allograft

Year:  2019        PMID: 30666744     DOI: 10.1002/jmri.26656

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  5 in total

1.  Is MRI relaxometry parameter T specific to fibrosis or confounded by concomitant pathological features?

Authors:  Stefanie J Hectors
Journal:  Quant Imaging Med Surg       Date:  2020-12

2.  Physiological variation of liver iron concentration may not be dominantly responsible for the liver T1rho variations associated with age and gender.

Authors:  Yì Xiáng J Wáng
Journal:  Quant Imaging Med Surg       Date:  2021-04

Review 3.  Noninvasive imaging assessment of portal hypertension.

Authors:  Paul Kennedy; Octavia Bane; Stefanie J Hectors; Aaron Fischman; Thomas Schiano; Sara Lewis; Bachir Taouli
Journal:  Abdom Radiol (NY)       Date:  2020-09-14

4.  Collagen deposition in the liver is strongly and positively associated with T1rho elongation while fat deposition is associated with T1rho shortening: an experimental study of methionine and choline-deficient (MCD) diet rat model.

Authors:  Feng Zhao; Nan Zhou; Ji-Li Wang; Hua Zhou; Li-Qiu Zou; Wei-Xiang Zhong; Jian He; Cun-Jing Zheng; Sen-Xiang Yan; Yì Xiáng J Wáng
Journal:  Quant Imaging Med Surg       Date:  2020-12

5.  T1ρ magnetic resonance imaging value as a potential marker to assess the severity of liver fibrosis: A pilot study.

Authors:  Yohsuke Suyama; Kengo Tomita; Shigeyoshi Soga; Hiroshi Kuwamura; Wakana Murakami; Ryota Hokari; Hiroshi Shinmoto
Journal:  Eur J Radiol Open       Date:  2021-01-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.